EDARBI

This brand name is authorized in Austria, Brazil, Canada, Germany, Estonia, Hong Kong, Croatia, Ireland, Lithuania, Poland, United Kingdom, United States

Active ingredients

The drug EDARBI contains one active pharmaceutical ingredient (API):

1 Azilsartan medoxomil UNII LL0G25K7I2 - AZILSARTAN MEDOXOMIL

Azilsartan medoxomil is an orally active prodrug that is rapidly converted to the active moiety, azilsartan, which selectively antagonises the effects of angiotensin II by blocking its binding to the AT1 receptor in multiple tissues. Angiotensin II is the principal pressor agent of the RAAS, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Read about Azilsartan medoxomil

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
EDARBI Tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C09CA09	Azilsartan medoxomil	C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09C Angiotensin II antagonists, plain → C09CA Angiotensin II antagonists, plain
Discover more medicines within C09CA09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 501114090023201
Country: CA	Health Products and Food Branch	Identifier(s): 02381389, 02381397
Country: DE	Bundesinstitut für Arzneimittel und Medizinprodukte	Identifier(s): 03100009, 03100021, 09252973, 09252996, 09253004, 09253027, 09253033, 09253056, 09253079, 09253085, 09253116, 13963964, 14293052, 14293069, 17394799
Country: EE	Ravimiamet	Identifier(s): 1550483, 1550494, 1550506, 1550517, 1550528, 1550539, 1550540, 1550551, 1550573, 1550584, 1550595, 1590285, 1590296, 1590308, 1590319, 1590320, 1590331, 1590342
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 203510, 203515, 203519
Country: HK	Department of Health Drug Office	Identifier(s): 61807, 61808
Country: IE	Health Products Regulatory Authority	Identifier(s): 51002, 51003, 51004
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1064204, 1064205, 1064206, 1064207, 1064208, 1064209, 1064210, 1064211, 1064212, 1064213, 1064214, 1067657, 1067658, 1067659, 1067660, 1067661, 1067662, 1067663, 1089479, 1089480, 1089481, 1089482, 1089483, 1089484, 1089485, 1089486, 1089487, 1089489, 1089490, 1089491
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100309540, 100309556, 100309562
Country: US	FDA, National Drug Code	Identifier(s): 60631-040, 60631-080